Documentos relacionados

1. Treatment of diffuse large B cell lymphoma.
2. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
3. [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].
4. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
5. Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems.
6. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
7. The multilobated morphology is still a better prognosis factor of diffuse large B-cell lymphoma in the R-CHOP era.
8. Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
9. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
10. Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation.